253 related articles for article (PubMed ID: 20473165)
1. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Eriksson B
Curr Opin Oncol; 2010 Jul; 22(4):381-6. PubMed ID: 20473165
[TBL] [Abstract][Full Text] [Related]
2. New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
Dong M; Phan AT; Yao JC
Clin Cancer Res; 2012 Apr; 18(7):1830-6. PubMed ID: 22338018
[TBL] [Abstract][Full Text] [Related]
3. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
4. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic neuroendocrine tumors: does chemotherapy work?
Tejani MA; Saif MW
JOP; 2014 Mar; 15(2):132-4. PubMed ID: 24618436
[TBL] [Abstract][Full Text] [Related]
6. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
7. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Raj N; Reidy-Lagunes D
Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
[TBL] [Abstract][Full Text] [Related]
8. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
9. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
10. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
11. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
12. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
14. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
17. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Reidy-Lagunes D; Thornton R
Curr Oncol Rep; 2012 Jun; 14(3):249-56. PubMed ID: 22434313
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic NETs: where do we stand now?
Faivre S; Castellano D; Strosberg J; González E; Salazar R
Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
